| Exudative age-related macular degeneration
Beovu vs Vabysmo
Side-by-side clinical, coverage, and cost comparison for exudative age-related macular degeneration.Deep comparison between: Beovu vs Vabysmo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVabysmo has a higher rate of injection site reactions vs Beovu based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vabysmo but not Beovu, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Beovu
Vabysmo
At A Glance
Intravitreal injection
Every 8-12 weeks (maintenance)
VEGF-A inhibitor
Intravitreal injection
Every 4-8 weeks
VEGF-A and Ang-2 inhibitor
Indications
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Macular retinal edema
Dosing
Exudative age-related macular degeneration 6 mg (0.05 mL) by intravitreal injection monthly (every 25-31 days) for first 3 doses, followed by 6 mg every 8-12 weeks.
Macular edema due to diabetes mellitus 6 mg (0.05 mL) by intravitreal injection every 6 weeks (every 39-45 days) for first 5 doses, followed by 6 mg every 8-12 weeks.
Exudative age-related macular degeneration 6 mg (0.05 mL) by intravitreal injection every 4 weeks for first 4 doses, followed by dosing every 8, 12, or 16 weeks based on OCT and visual acuity evaluations; some patients may need every 4-week dosing.
Macular edema due to diabetes mellitus 6 mg (0.05 mL) by intravitreal injection every 4 weeks for at least 4-6 doses, then interval adjusted to every 4-8 weeks based on CST and visual acuity evaluations.
Macular retinal edema 6 mg (0.05 mL) by intravitreal injection every 4 weeks.
Contraindications
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to brolucizumab or any excipient in BEOVU
- Ocular or periocular infection
- Active intraocular inflammation
- Known hypersensitivity to faricimab or any excipient in VABYSMO
Adverse Reactions
Most common (>=1%) Vision blurred, cataract, conjunctival hemorrhage, vitreous floaters, eye pain, intraocular inflammation, intraocular pressure increased, retinal hemorrhage, vitreous detachment, conjunctivitis, retinal pigment epithelial tear, corneal abrasion, hypersensitivity, punctate keratitis, retinal tear, endophthalmitis, blindness, retinal artery occlusion, retinal detachment, conjunctival hyperemia, lacrimation increased, abnormal sensation in eye, detachment of retinal pigment epithelium, vitreous hemorrhage
Serious Endophthalmitis, retinal detachment, retinal vasculitis, retinal vascular occlusion, intraocular pressure increase, thromboembolic events, hypersensitivity
Most common (>=1%) Conjunctival hemorrhage, cataract, vitreous detachment, vitreous floaters, intraocular pressure increased, eye pain, intraocular inflammation, retinal pigment epithelial tear, eye irritation, lacrimation increased, ocular discomfort
Serious Endophthalmitis, retinal detachment, increase in intraocular pressure, thromboembolic events, retinal vasculitis and/or retinal vascular occlusion
Postmarketing Retinal vasculitis with or without retinal vascular occlusion
Pharmacology
VEGF-A inhibitor; brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment that binds the three major isoforms of VEGF-A (VEGF110, VEGF121, VEGF165), blocking VEGFR-1 and VEGFR-2 interaction to suppress endothelial cell proliferation, neovascularization, and vascular permeability.
Faricimab is a humanized bispecific antibody that inhibits two pathways by binding to VEGF-A and Ang-2; VEGF-A inhibition suppresses endothelial cell proliferation, neovascularization, and vascular permeability, while Ang-2 inhibition promotes vascular stability and desensitizes blood vessels to the effects of VEGF-A.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Beovu
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
Vabysmo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Beovu
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vabysmo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Beovu
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Vabysmo
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VabysmoView full Vabysmo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.